Skip to main content

Table 5 Drug interactions of HCV Direct Acting Antiviral agents with ARTa

From: Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

HCV DAA

ART drug name

Effect on concentration

Comments

Sofosbuvir/Velpatasvir

 

Efavirenz

↓ velpatasvir

Coadministration not recommended

Tenofovir disoproxil (TDF)

↑ tenofovir

Renal monitoring for tenofovir associated adverse reactions.

Tipranavir/ritonavir

↓ sofosbuvir

↓ velpatasvir

Coadministration not recommended

Glecaprevir/Pibrentasvir

 

Atazanavir

↑ glecaprevir

↑ pibrentasvir

Coadministration contraindicated due to increased risk of ALT elevations

Darunavir/Lopinivir/ritonovir

↑ glecaprevir

↑ pibrentasvir

Coadministration not recommended

Efavirenz

↓ glecaprevir

↓ pibrentasvir

Coadministration not recommended

  1. DAA direct acting antiviral, HCV hepatitis C virus, ALT alanine aminotransferase
  2. aReference: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954